Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone

Sobolevsky, Tim; Kucherova, Y.; Ahrens, B.

doi:10.1002/dta.2353

Cited by 3 publications

(1 citation statement)

References 8 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, characteristic metabolites of mebeverine or oxethazaine are to be monitored in cases of potential AAFs related to p ‐hydroxy‐amphetamine or phentermine and mephentermine, respectively, 72,73 as the permitted use of mebeverine and oxethazaine is to be differentiated from the prohibited administrations of stimulants such as amphetamine, phentermine, and their derivatives. Further, in another case, the degradation products oxymorphone and naltrexone were identified as the degradation products of the permitted drug methylnaltrexone in urine and determine not to be from administration of oxymorphone 74 . While the metabolic pathways of these drugs have been thoroughly investigated and described in the literature, also unexpected sequential metabolic conversions leading to prohibited substances in doping control urine samples were recorded.…”

Section: Scenarios Of Potential Suspected And/or Proven Exposure‐caused Aafsmentioning

confidence: 99%

Sports drug testing and the athletes' exposome

Thevis

Kuuranne

Fedoruk

et al. 2021

Drug Testing and Analysis

View full text Add to dashboard Cite

Similar to the general population, elite athletes are exposed to a complex set of environmental factors including chemicals and radiation and also biological and physical stressors, which constitute an exposome that is, unlike for the general population, subjected to specific scrutiny for athletes due to applicable antidoping regulations and associated (frequent) routine doping controls. Hence, investigations into the athlete's exposome and how to distinguish between deliberate drug use and different contamination scenarios has become a central topic of antidoping research, as a delicate balance is to be managed between the vital and continually evolving developments of sensitive analytical techniques on the one hand, and the risk of the athletes' exposome potentially causing adverse analytical findings on the other.

show abstract

Section: Scenarios Of Potential Suspected And/or Proven Exposure‐caused Aafsmentioning

confidence: 99%

Sports drug testing and the athletes' exposome

Thevis

Kuuranne

Fedoruk

et al. 2021

Drug Testing and Analysis

View full text Add to dashboard Cite

show abstract

Methylnaltrexone bromide for the treatment of opioid-induced constipation

Mozaffari

Nikfar

Abdollahi

2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

The extensive and alarming use of opioids for pain management in patients with chronic pain receiving palliative care is associated with non-tolerable gastrointestinal (GI) adverse effects. Opioid-induced constipation (OIC) is the most common adverse effect impairing patient quality of life (QOL). In addition, OIC is one of the treatment limiting consequences of opioid analgesics. Management of OIC is becoming a challenge since traditional laxatives have limited efficiency. Peripherally acting mu-opioid receptor antagonists (PAMORA) have been developed for the treatment of OIC with methylnaltrexone bromide being the first approved to treat OIC in adults with advanced illness undergoing palliative care. Areas covered: The authors systematically review the clinical evidence for methylnaltrexone bromide including a review of the pharmacokinetic and pharmacodynamic data along with clinical effectiveness and cost-effectiveness. Though there is a need for further long-term clinical investigation, there is a large body of evidence for both its efficacy and safety in the treatment of OIC. Expert opinion: Methylnaltrexone has both subcutaneous injection and oral dosage forms available in the market. The lack of more evidence in specific populations such as pregnant women, pediatrics and elderly still remains. The global consumption of methylnaltrexone shows a projection of increased use since its approval worldwide in 2008.

show abstract

Impact of the Opioid Epidemic on Drug Testing

McMillin

Johnson-Davis

Kelly

et al. 2021

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Background: This review provides a description of how the opioid epidemic has impacted drug testing. Methods: Four major service areas of drug testing were considered, including emergency response, routine clinical care, routine forensics, and death investigations. Results: Several factors that the opioid epidemic has impacted in drug testing are discussed, including specimens, breadth of compounds recommended for testing, time to result required for specific applications, analytical approaches, interpretive support requirements, and examples of published practice guidelines. Conclusions: Both clinical and forensic laboratories have adapted practices and developed new testing approaches to respond to the opioid epidemic. Such changes are likely to continue evolving in parallel with changes in both prescription and nonprescription opioid availability and use patterns, as well as emerging populations that are affected by the “waves” of the opioid epidemic.

show abstract

Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone

Cited by 3 publications

References 8 publications

Sports drug testing and the athletes' exposome

Sports drug testing and the athletes' exposome

Methylnaltrexone bromide for the treatment of opioid-induced constipation

Impact of the Opioid Epidemic on Drug Testing

Contact Info

Product

Resources

About